

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



Sirnaomics Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2257)

COMPLETION OF SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

Reference is made to the announcements of Sirnaomics Ltd. (the “**Company**”) dated May 23, 2026 and June 1, 2026 (the “**Announcements**”) in relation to, among other matters, the Subscription. Unless otherwise defined, capitalised terms used herein have the same meanings as defined in the Announcements.

COMPLETION OF THE SUBSCRIPTION

The Board is pleased to announce that all conditions precedent of the Subscription Agreement have been fulfilled and the completion of the Subscription took place on August 12, 2026. An aggregate of 2,435,600 Subscription Shares, representing approximately 2.17% of the number of the issued Shares immediately after Completion, have been allotted and issued to the Subscriber at the Subscription Price of HK\$4.69 per Subscription Share pursuant to the terms and conditions of the Subscription Agreement. The net proceeds from the Subscription are approximately HK\$11.3 million. The Group intends to use the proceeds from the Subscription for its general working capital.

EFFECT ON SHAREHOLDING STRUCTURE OF THE COMPANY

The table below sets out the changes to the shareholding structure of the Company immediately prior to and after Completion:

	Immediately prior to Completion		Immediately after Completion	
	<i>Number of Shares</i>	<i>Approximate %</i>	<i>Number of Shares</i>	<i>Approximate %</i>
Directors, chief executive or substantial shareholders of the Company or their close associates				
Dr. Poon Hung Fai (<i>Note 1</i>)	17,685,996	16.12%	17,685,996	15.77%
Subscriber	1,012,500	0.92%	3,448,100	3.07%
Other public Shareholders	<u>91,023,042</u>	<u>82.96%</u>	<u>91,023,042</u>	<u>81.16%</u>
Total	<u>109,721,538</u>	<u>100.00%</u>	<u>112,157,138</u>	<u>100.00%</u>

Note:

- (1) Quarmaceutical Limited is wholly owned by Dr. Poon Hung Fai (“**Dr. Poon**”). The above table shows Dr. Poon’s shareholdings consisting of: (a) 17,527,696 Shares held by Quarmaceutical Limited; and (b) 158,300 Shares beneficially owned by Dr. Poon.

By order of the Board
Sirnaomics Ltd.
Poon Hung Fai
Chairman and Executive Director

Hong Kong, August 12, 2026

As at the date of this announcement, the Board comprises Dr. Poon Hung Fai as executive Director, Dr. Yin Huijun as non-executive Director, and Mr. Wong Yu Shan Eugene, Dr. Zhang Peng and Ms. Lo Yee Hang as independent non-executive Directors.